Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Global health initiatives news

Show

From To
The HIV 'emergency' isn't over, says PEPFAR chief

Ambassador Deborah Birx, U.S. global AIDS coordinator and director of the largest initiative to combat a single disease, talks data, PEPFAR's future and the AIDS emergency we still face in this video interview.

Published
18 hours ago
From
Devex
UNAIDS welcomes further evidence that starting antiretroviral therapy early saves lives

“Every person living with HIV should have immediate access to life-saving antiretroviral therapy,” said Michel Sidibé, Executive Director of UNAIDS. “Delaying access to HIV treatment under any pretext is denying the right to health.”

Published
28 May 2015
From
UNAIDS
ViiV Healthcare and CHAI collaboration delivers second milestone with first filing with the FDA of generic dolutegravir by Aurobindo Pharma for the treatment of HIV

ViiV Healthcare, Aurobindo Pharma, and the Clinton Health Access Initiative, Inc. (CHAI) announced today that Aurobindo Pharma has submitted an Abbreviated New Drug Application (ANDA) for dolutegravir 50mg, for Tentative Approval, to the Food and Drug Administration (FDA), for the treatment of HIV. This is the first ANDA for a generic version of dolutegravir, less than two years after FDA approval of Tivicay® (dolutegravir) for sale in the United States. Upon receiving Tentative Approval from the FDA, Aurobindo Pharma will be able to supply dolutegravir 50mg via the President’s Emergency Plan for AIDS Relief (PEPFAR) programme, following completion of required local regulatory approval process, in the licensed countries outside of the United States, as per the agreement signed between Aurobindo Pharma and ViiV Healthcare in 2014.

Published
26 May 2015
From
ViiV Healthcare
WHO Advances Research and Development Financing Effort; Global R&D Observatory To Launch In January

World Health Organization members in committee this week took note of a report by the Consultative Expert Working Group on Research and Development: Financing and Coordination (CEWG), which was set up to find ways to fund research on diseases afflicting poor populations which have little market incentive for the private sector. The report included a proposal for a voluntary pooled fund that would focus on the development of effective and affordable health technologies for such neglected diseases.

Published
26 May 2015
From
Intellectual Property Watch
World Health Assembly: Experts discuss delinking drug R&D costs from pricing to make them affordable

The problem of drug prices eating up national health budgetscame up at the annual World Health Assembly, which took place from 18-26 May. Last week, a panel of experts discussed the merits of lowering those prices by delinking research and development costs from pricing.

Published
26 May 2015
From
Intellectual Property Watch
Funders' priorities and targets hindered community mobilisation and meaningful participation of sex workers in India

Two qualitative studies, investigating the implementation of a massive programme of HIV prevention through community mobilisation in India, have identified challenges to the rapid scale-up and roll-out

Published
25 May 2015
By
Roger Pebody
Civil Society Groups Tell UNITAID: Support access mechanisms led by civil society, not the pharmaceutical industry

Letters from global groups express deep concerns about the Medicines Patent Pool’s entry into hepatitis C treatment.

Published
05 May 2015
From
Hep C Coalition
Pre-exposure prophylaxis works—it's time to deliver

The science is now clear: oral pre-exposure prophylaxis (PrEP) with a coformulation of tenofovir disoproxil fumarate and emtricitabine (Truvada) significantly reduces the risk of HIV infection among individuals at high risk of HIV infection. The news that PrEP has shown consistent efficacy among those who take it as prescribed should be a cause for celebration, and galvanise action to ensure access to PrEP for those who could benefit the most.

Published
17 April 2015
From
The Lancet
"Finally, the Global Fund is focused on human beings": Dybul delivers executive director's report

Switching gears from a typical executive director's report to the Board during the Global Fund's 33rd meeting on 31 March, Mark Dybul reflected on the six trips he had made in the first quarter of 2015 that demonstrated what he said were the breadth and flexibility inherent in the new funding model.

Published
02 April 2015
From
Global Fund Observer
Alert: Serbia is losing harm reduction

The situation with harm reduction in Serbia is getting increasingly alarming after withdrawal of the Global Fund. Three organizations doing HR programs in Serbia for more than a decade are struggling to maintain services. We want a different future for their beneficiaries. ""Please use your communication with donors to put Serbia back as eligible for funding the harm reduction programs - we keep knocking on closed doors. The EU is the biggest donor here and has no health programs whatsoever; as for other donors, we are ineligible whomever we approach, and keep losing on relevance to the calls,“ says Miodrag Atanasjevic, NGO Veza, Belgrade, Serbia.

Published
02 April 2015
From
Eurasian Harm Reduction Network
← First12345...66Next →

Filter by country